Analysts Offer Insights on Healthcare Companies: Immune Design (NASDAQ: IMDZ) and Array Biopharma (NASDAQ: ARRY)

By Austin Angelo

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immune Design (NASDAQ: IMDZ) and Array Biopharma (NASDAQ: ARRY) with bullish sentiments.

Immune Design (NASDAQ: IMDZ)

In a report issued on November 10, Boris Peaker from Cowen & Co. reiterated a Buy rating on Immune Design (NASDAQ: IMDZ). The company’s shares closed last Friday at $8.30.

Peaker commented:

“IMDZ reported 3Q earnings and provided a pipeline update.”

According to TipRanks.com, Peaker is a 5-star analyst with an average return of 12.4% and a 48.6% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Inc., Corvus Pharmaceuticals Inc, and Corcept Therapeutics Inc.

Currently, the analyst consensus on Immune Design is Moderate Buy and the average price target is $15, representing an 80.7% upside.

In a report issued on November 9, Jefferies also reiterated a Buy rating on the stock with a $15 price target.
Array Biopharma (NASDAQ: ARRY)

Cowen & Co. analyst Chris Shibutani reiterated a Buy rating on Array Biopharma (NASDAQ: ARRY) on November 9 and set a price target of $10. The company’s shares closed last Friday at $6.74, close to its 52-week high of $7.27.

Shibutani commented:

“Detailed results from Part 1 of the COLUMBUS trial presented at the SMR Congress.”

According to TipRanks.com, Shibutani is a 5-star analyst with an average return of 15.2% and a 78.9% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, United Therapeutics, and Puma Biotechnology.

Currently, the analyst consensus on Array Biopharma is Strong Buy and the average price target is $9.17, representing a 36.1% upside.

In a report issued on November 1, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $13 price target.